Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
This review (2021) presents the neurobiological therapeutic mechanisms by which psychedelics work, with a focus on outcomes on 1) neuroplasticity, 2) immune system, and 3) effects on neurotransmitter (-modulator) systems.
Authors
- De Gregorio, D.
- Gobbi, G.
- Inserra, A.
Published
Abstract
Mounting evidence suggests safety and efficacy of psychedelic compounds as potential novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug Administration in a new class of antidepressants, and 3,4-methylenedioxymethamphetamine (MDMA) is undergoing phase III clinical trials for post-traumatic stress disorder. Psilocybin and lysergic acid diethylamide (LSD) are being investigated in several phase II and phase I clinical trials. Hence, the concept of psychedelics as therapeutics may be incorporated into modern society. Here, we discuss the main known neurobiological therapeutic mechanisms of psychedelics, which are thought to be mediated by the effects of these compounds on the serotonergic (via 5-HT2A and 5-HT1A receptors) and glutamatergic [via N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] systems. We focus on 1) neuroplasticity mediated by the modulation of mammalian target of rapamycin-, brain-derived neurotrophic factor-, and early growth response-related pathways; 2) immunomodulation via effects on the hypothalamic-pituitary-adrenal axis, nuclear factor ĸB, and cytokines such as tumour necrosis factor-α and interleukin 1, 6, and 10 production and release; and 3) modulation of serotonergic, dopaminergic, glutamatergic, GABAergic, and norepinephrinergic receptors, transporters, and turnover systems. We discuss arising concerns and ways to assess potential neurobiological changes, dependence, and immunosuppression. Although larger cohorts are required to corroborate preliminary findings, the results obtained so far are promising and represent a critical opportunity for improvement of pharmacotherapies in psychiatry, an area that has seen limited therapeutic advancement in the last 20 years. Studies are underway that are trying to decouple the psychedelic effects from the therapeutic effects of these compounds.
Research Summary of 'Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms'
Study Details
- Study Typemeta
- Populationhumans
- Characteristicsliterature review
- Journal
- Compounds
Cited By (38)
Papers in Blossom that reference this study
Austin, E. W., Borghans, L. G. J. M., Christian, E. P. et al. · Journal of Psychopharmacology (2025)
Beliveau, V., Fisher, P. M., Geisler, M. et al. · Research Square (2025)
Aarrestad, I. K., Barragan, E. V., Cameron, L. P. et al. · Nature Neuroscience (2025)
de Wit, H., Glazer, J., Haggarty, C. J. et al. · Psychedelic Medicine (2024)
Croal, M., Goodwin, G. M., Marwood, L. et al. · Journal of Psychiatric Research (2024)
Doss, M. K., Kloft, L., Mallaroni, P. et al. · Journal of Psychopharmacology (2024)
Agnorelli, C., Bohl, B., Carhart-Harris, R. L. et al. · Preprints (2024)
Argento, E., Brendle, M., Girn, M. et al. · Journal of Psychopharmacology (2024)
Cassidy, K., D'Andrea, W., Healy, C. J. et al. · Drug Science Policy and Law (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Show all 38 papersShow fewer
Greń, J., Kiraly, C., Lasocik, M. et al. · Frontiers in Psychology (2023)
González-Maeso, J., Jaster, A. M. · Molecular Psychiatry (2023)
Barnett, B. S., Claytor, B., Kovacevich, A. et al. · Journal of Psychoactive Drugs (2023)
Frecska, E., Szabo, A., Winkelman, M. J. · European Neuropsychopharmacology (2023)
Carhart-Harris, R. L., Chiacchiaretta, P., Ferretti, A. et al. · Biological Psychiatry (2023)
Abizaid, A., Aguilar-Valles, A., Arsenault, E. et al. · Cell Reports (2023)
Aripaka, S. S., Burmester, D., Elfving, B. et al. · Comprehensive Psychoneuroendocrinology (2023)
Barragan, E. V., Cameron, L. P., Chow, W. L. et al. · ACS Chemical Neuroscience (2023)
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Castle, D., Downey, L., Galvão-Coelho, N. L. et al. · Neuropsychopharmacology (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dourron, H. M., Hendricks, P. S., Strauss, C. · Pharmacological Reviews (2022)
Egan, G. F., Friston, K. J., Razi, A. et al. · Pharmacological Reviews (2022)
Araújo, D. B., Falchi, M., Feilding, A. et al. · European Neuropsychopharmacology (2022)
Comai, S., De Gregorio, D., Enns, J. P. et al. · Neuropsychopharmacology (2022)
Olson, D. E. · Biochemistry (2022)
Carvalho, A. F., Chu, C-S., Hsu, C-W. et al. · Journal of Clinical Medicine (2022)
Smallridge, J. W., Vollenweider, F. X. · Pharmacopsychiatry (2022)
De Gregorio, D., Gobbi, G., Inserra, A. et al. · Frontiers in Pharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Clarke, G., Gillan, C. M., Harkin, A. et al. · Frontiers in Psychiatry (2021)
Guillaume, S., Strumila, R. · Pharmaceuticals (2021)
Baker, J. J., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Cleary, S., Corrigan, K., Haran, M. et al. · Irish Journal of Medical Science (2021)
Banks, M. I., Jones, N. T., Sultan, Z. W. et al. · Molecular Biology of the Cell (2021)
Breslow, L., Singhal, N., Weissman, C. R. et al. · ACS Pharmacology and Translational Science (2021)
Aguilar-Valles, A., De Gregorio, D., Gobbi, G. et al. · Journal of Neuroscience (2020)